Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income: 2023-2025

Historic Net Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Net Income fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.38% down from last year.
  • Day One Biopharmaceuticals' Net Income amounted to -$19.7 million in Q3 2025, which was up 35.02% from -$30.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Net Income's 5-year high stood at $35.8 million during Q3 2024, with a 5-year trough of -$112.4 million in Q2 2024.
  • Its 3-year average for Net Income is -$43.4 million, with a median of -$44.3 million in 2023.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Net Income showed a top increase of 177.66% in 2024 and a maximum decrease of 165.16% in 2024.
  • Day One Biopharmaceuticals' Net Income (Quarterly) stood at -$54.5 million in 2023, then fell by 20.61% to -$65.7 million in 2024, then plummeted by 154.94% to -$19.7 million in 2025.
  • Its last three reported values are -$19.7 million in Q3 2025, -$30.3 million for Q2 2025, and -$36.0 million during Q1 2025.